跳至主要内容
临床试验/NCT00078221
NCT00078221Unknown3 期

Rheopheresis Blood Filtration Study for the Treatment of Dry Age-Related Macular Degeneration (AMD)

OccuLogix15 个研究点 分布在 2 个国家目标入组 180 人开始时间: 1999年8月1日最近更新:
适应症

试验速览

阶段
3 期
发起方
OccuLogix
入组人数
180
试验地点
15

研究概览

简要总结

AMD is a progressive disease of the retina which is nourished by a network of tiny blood vessels. There is evidence to suggest that the flow of nutrients to the retina is impaired in patients with AMD. Rheopheresis blood filtration uses blood filters that deplete excesses of large proteins, fats and other substances from the blood, improving blood flow to the macula, potentially improving vision.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Treatment
盲法
Double

入排标准

年龄范围
50 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age 50-85
  • Diagnosis of Dry AMD
  • BCVA between 20/32 and 20/125 in at least one eye
  • Numerous large plaques (soft drusen)
  • No history of HIV, Hepatitis B or C
  • Elevation of certain blood factors, such as total cholesterol, fibrinogen, and IgA

排除标准

  • 未提供

研究者

发起方
OccuLogix
申办方类型
Industry

研究点 (15)

Loading locations...

相似试验